Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · Real-Time Price · USD
0.2541
-0.0441 (-14.79%)
At close: Jun 5, 2026, 4:00 PM EDT
0.2480
-0.0061 (-2.40%)
After-hours: Jun 5, 2026, 7:59 PM EDT
Ensysce Biosciences Employees
As of December 31, 2025, Ensysce Biosciences had 10 total employees, including 8 full-time and 2 part-time employees. The number of employees increased by 2 or 25.00% compared to the previous year.
Employees
10
Change (1Y)
2
Growth (1Y)
25.00%
Revenue / Employee
$470,788
Profits / Employee
-$1,178,654
Market Cap
2.36M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 10 | 2 | 25.00% | 8 | 2 |
| Dec 31, 2024 | 8 | 1 | 14.29% | 7 | 1 |
| Dec 31, 2023 | 7 | 0 | - | 7 | 0 |
| Dec 31, 2022 | 7 | 1 | 16.67% | 7 | 0 |
| Dec 31, 2021 | 6 | 3 | 100.00% | 6 | 0 |
| Sep 30, 2021 | 4 | 1 | 33.33% | 4 | 0 |
| Jun 30, 2021 | 4 | - | - | 4 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Valion Bio | 52 |
| Calidi Biotherapeutics | 29 |
| Silexion Therapeutics | 14 |
| Azitra | 13 |
| Biodexa Pharmaceuticals | 11 |
| Decoy Therapeutics | 11 |
| Adial Pharmaceuticals | 5 |
| GRI Bio | 4 |
ENSC News
- 2 days ago - Ensysce Biosciences files to sell 1.3M shares of common stock for holders - TheFly
- 3 days ago - Ensysce Biosciences Registration statement: Registration filing - Filings
- 23 days ago - Ensysce Biosciences Reports First Quarter 2026 Financial Results - Accesswire
- 23 days ago - Ensysce Biosciences Quarterly report: Q1 2026 - Filings
- 23 days ago - Ensysce Biosciences Earnings release: Q1 2026 - Filings
- 26 days ago - Ensysce announces expansion of patent protection for MPAR technology - TheFly
- 26 days ago - Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology - Accesswire
- 4 weeks ago - Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam - Accesswire